The potential of NORAD–PUMILIO–RALGAPB regulatory axis as a biomarker in breast cancer

dc.creatorMuller, Cristiane Sato Mara
dc.creatorGiner, Igor Samesima
dc.creatorZambalde, Érika Pereira
dc.creatorCarvalho, Tamyres Mingorance
dc.creatorRibeiro, Enilze Maria de Souza Fonseca
dc.creatorOliveira, Jaqueline Carvalho de
dc.creatorMathias, Carolina
dc.creatorGradia, Daniela Fiori
dc.date2023-01-12T13:57:50Z
dc.date2023-01-12T13:57:50Z
dc.date2022
dc.date.accessioned2023-09-26T20:09:48Z
dc.date.available2023-09-26T20:09:48Z
dc.identifierMULLER, Cristiane Sato Mara et al. The potential of NORAD–PUMILIO–RALGAPB regulatory axis as a biomarker in breast cancer. Non-Coding RNA, v.8, n. 76, p. 1–12, 2022.
dc.identifier2311-553X
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/56445
dc.identifier10.3390/ ncrna8060076
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8850106
dc.descriptionLong non-coding RNAs (LncRNA) represent a heterogeneous family of RNAs that have emerged as regulators of various biological processes through their association with proteins in ribonucleoproteins complexes. The dynamic of these interactions can affect cell metabolism, including cancer development. Annually, breast cancer causes thousands of deaths worldwide, and searching for new biomarkers is pivotal for better diagnosis and treatment. Based on in silico prediction analysis, we focus on LncRNAs that have binding sites for PUMILIO, an RBP family involved in post- transcriptional regulation and associated with cancer progression. We compared the expression levels of these LncRNAs in breast cancer and non-tumor samples from the TCGA database. We analyzed the impact of overall and disease-free survival associated with the expression of the LncRNAs and co-expressed genes and targets of PUMILIO proteins. Our results found NORAD as the most relevant LncRNA with a PUMILIO binding site in breast cancer, differently expressed between Luminal A and Basal subtypes. Additionally, NORAD was co-expressed in a Basal-like subtype (0.55) with the RALGAPB gene, a target gene of PUMILIO related to chromosome stability during cell division. These data suggest that this molecular axis may provide insights for developing novel therapeutic strategies for breast cancer.
dc.formatapplication/pdf
dc.languagepor
dc.publisherMDPI
dc.rightsopen access
dc.subjectLncRNA
dc.subjectNORAD
dc.subjectPumilio
dc.subjectRALGAPB
dc.subjectRNA, Long Noncoding
dc.subjectGTPase-Activating Proteins
dc.subjectDNA Damage
dc.subjectBreast Cancer
dc.subjectBiomarkers
dc.subjectARN Largo no Codificante
dc.subjectProteínas Activadoras de GTPasa
dc.subjectDaño del ADN
dc.subjectNeoplasias de la Mama
dc.subjectBiomarcadores
dc.subjectARN long non codant
dc.subjectProtéines d'activation de la GTPase
dc.subjectAltération de l'ADN
dc.subjectTumeurs du sein
dc.subjectMarqueurs biologiques
dc.subjectRNA Longo não Codificante
dc.subjectProteínas Ativadoras de GTPase
dc.subjectDano ao DNA
dc.subjectNeoplasias da Mama
dc.subjectBiomarcadores
dc.titleThe potential of NORAD–PUMILIO–RALGAPB regulatory axis as a biomarker in breast cancer
dc.typeArticle


Este ítem pertenece a la siguiente institución